These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33647028)

  • 41. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD161
    Li X; Liu Z; Li Q; Hu R; Zhao L; Yang Y; Zhao J; Huang Z; Gao H; Li L; Cai W; Deng K
    mBio; 2019 Oct; 10(5):. PubMed ID: 31594817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific Activation
    Li G; Zhang Z; Reszka-Blanco N; Li F; Chi L; Ma J; Jeffrey J; Cheng L; Su L
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30971469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.
    Omondi FH; Chandrarathna S; Mujib S; Brumme CJ; Jin SW; Sudderuddin H; Miller RL; Rahimi A; Laeyendecker O; Bonner P; Yue FY; Benko E; Kovacs CM; Brockman MA; Ostrowski M; Brumme ZL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production.
    Andrade RM; Lima PG; Filho RG; Hygino J; Milczanowski SF; Andrade AF; Lauria C; Brindeiro R; Tanuri A; Bento CA
    AIDS; 2007 Aug; 21(13):1763-70. PubMed ID: 17690575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
    Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
    EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gradual shutdown of virus production resulting in latency is the norm during the chronic phase of human immunodeficiency virus replication and differential rates and mechanisms of shutdown are determined by viral sequences.
    Li XD; Moore B; Cloyd MW
    Virology; 1996 Nov; 225(1):196-212. PubMed ID: 8918547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infectious Virus Persists in CD4
    Abreu CM; Veenhuis RT; Avalos CR; Graham S; Queen SE; Shirk EN; Bullock BT; Li M; Metcalf Pate KA; Beck SE; Mangus LM; Mankowski JL; Clements JE; Gama L
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31118264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
    Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.
    Wen J; Yan M; Liu Y; Li J; Xie Y; Lu Y; Kamata M; Chen IS
    PLoS One; 2016; 11(4):e0151572. PubMed ID: 27049645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective cell death of latently HIV-infected CD4
    Zhang G; Luk BT; Wei X; Campbell GR; Fang RH; Zhang L; Spector SA
    Cell Death Dis; 2019 May; 10(6):419. PubMed ID: 31142734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selected P. falciparum specific immune responses are maintained in AIDS adults in Burkina Faso.
    Migot F; Ouedraogo JB; Diallo J; Zampan H; Dubois B; Scott-Finnigan T; Sanou PT; Deloron P
    Parasite Immunol; 1996 Jul; 18(7):333-9. PubMed ID: 9229386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood.
    Hocini H; Bonnabau H; Lacabaratz C; Lefebvre C; Tisserand P; Foucat E; Lelièvre JD; Lambotte O; Saez-Cirion A; Versmisse P; Thiébaut R; Lévy Y
    J Virol; 2019 May; 93(10):. PubMed ID: 30814287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
    Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
    J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.
    Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I
    J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.